Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:BRM TSE:MDNA NASDAQ:ME CVE:NBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBRMBioRemC$3.39C$2.64C$1.67▼C$3.40C$54.70M1.00585226,530 shs9,229 shsMDNAMedicenna TherapeuticsC$0.62C$0.71C$0.54▼C$1.97C$51.72M2.84393107,722 shs39,629 shsME23andMe$0.61$0.50$0.53▼$9.57$16.27M1.191.57 million shsN/ANBYNiobay MetalsC$0.08C$0.10C$0.06▼C$0.39C$14.05M1.593041228,677 shs354,766 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBRMBioRem0.00%+0.93%+34.02%+23.86%+81.67%MDNAMedicenna Therapeutics0.00%0.00%-1.61%-29.89%-41.90%ME23andMe0.00%0.00%0.00%+21.75%+21.75%NBYNiobay Metals0.00%-5.88%-11.11%-40.74%+33.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBRMBioRemC$3.39C$2.64C$1.67▼C$3.40C$54.70M1.00585226,530 shs9,229 shsMDNAMedicenna TherapeuticsC$0.62C$0.71C$0.54▼C$1.97C$51.72M2.84393107,722 shs39,629 shsME23andMe$0.61$0.50$0.53▼$9.57$16.27M1.191.57 million shsN/ANBYNiobay MetalsC$0.08C$0.10C$0.06▼C$0.39C$14.05M1.593041228,677 shs354,766 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBRMBioRem0.00%+0.93%+34.02%+23.86%+81.67%MDNAMedicenna Therapeutics0.00%0.00%-1.61%-29.89%-41.90%ME23andMe0.00%0.00%0.00%+21.75%+21.75%NBYNiobay Metals0.00%-5.88%-11.11%-40.74%+33.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBRMBioRem 0.00N/AN/AN/AMDNAMedicenna Therapeutics 0.00N/AN/AN/AME23andMe 0.00N/AN/AN/ANBYNiobay Metals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBRMBioRemC$42.36M1.29C$0.92 per share3.70C$0.93 per share3.66MDNAMedicenna TherapeuticsN/AN/AC$0.54 per share1.15C$0.07 per shareN/AME23andMe$208.78M0.08$0.65 per share0.93$2.34 per share0.26NBYNiobay MetalsN/AN/AC$0.06 per share1.31C$0.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBRMBioRemC$5.40MC$0.2613.04N/AN/A11.37%39.51%14.61%N/AMDNAMedicenna Therapeutics-C$25.98M-C$0.15N/AN/AN/A-533,640.00%-103.51%-32.80%N/AME23andMe-$666.70M-$15.45N/AN/AN/A-183.39%-170.07%-62.13%N/ANBYNiobay Metals-C$2.11M-C$0.02N/AN/AN/AN/A-60.70%-40.09%N/ALatest NBY, BRM, MDNA, and ME EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/30/2026Q1 2026MDNAMedicenna TherapeuticsN/A-C$0.06N/A-C$0.06N/AN/A2/13/2026Q3 2026MDNAMedicenna TherapeuticsN/A-C$0.05N/A-C$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBRMBioRemN/A6.47%N/AN/AN/AMDNAMedicenna TherapeuticsN/AN/AN/AN/AN/AME23andMeN/AN/AN/AN/AN/ANBYNiobay MetalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBRMBioRem18.971.851.08MDNAMedicenna Therapeutics3.302.684.65ME23andMeN/A1.050.91NBYNiobay MetalsN/A9.0310.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBRMBioRem0.15%MDNAMedicenna Therapeutics0.43%ME23andMe36.10%NBYNiobay Metals0.78%Insider OwnershipCompanyInsider OwnershipBRMBioRem1.90%MDNAMedicenna Therapeutics22.57%ME23andMe26.32%NBYNiobay Metals18.91%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBRMBioRem34,30016.14 millionN/ANot OptionableMDNAMedicenna Therapeutics2083.42 millionN/ANot OptionableME23andMe77026.83 million19.77 millionNot OptionableNBYNiobay Metals30187.31 millionN/ANot OptionableNBY, BRM, MDNA, and ME HeadlinesRecent News About These CompaniesCome Meet NioBay Metals at PDAC 2026 in TorontoFebruary 27, 2026 | finance.yahoo.comNioBay Metals Inc.: Update for the James Bay Niobium ProjectFebruary 21, 2026 | finanznachrichten.deAnalysts Remain Bullish on Osisko Development as It Acquires 8.57 Million Units of Niobay Metals Inc.January 9, 2026 | finance.yahoo.comOsisko Development buying at Niobay Metals (NBY)December 26, 2025 | theglobeandmail.comOsisko Development and Electric Elements File Early Warning Report for Niobay Metals Inc.December 23, 2025 | financialpost.comFNioBay Metals Inc.: NioBay Metals Announces Closing of Brokered Life Offering and Concurrent Private Placement for Gross Proceeds of C$8.9 MillionDecember 19, 2025 | finanznachrichten.deNioBay Metals raises C$8.9 million to advance James Bay niobium projectDecember 19, 2025 | msn.comNioBay Metals Announces Upsize of Brokered LIFE Offering and Concurrent Private Placement to Gross Proceeds of Up to C$7.5 MillionDecember 4, 2025 | markets.businessinsider.comNiobay Metals Improves the Concentrate Content by 56% as Compared to Historical Metallurgical ResultsOctober 21, 2025 | juniorminingnetwork.comGreen light: Ontario approves NioBay’s James Bay exploration planOctober 13, 2025 | canadianminingjournal.comCNioBay Confirms Receipt of an Exploration Permit for its James Bay Niobium ProjectOctober 9, 2025 | finance.yahoo.comNiobay Metals Confirms Extension of Mineralization on Its Crevier Project and Intersects Rare Earth Elements in Its Northernmost HolesSeptember 11, 2025 | juniorminingnetwork.comNiobay Metals Inc. (NBY.V) - Yahoo FinanceJune 26, 2025 | sg.finance.yahoo.comNioBay Metals Inc.: NioBay Announces the Start of Its 2025 Drill Campaign on Its Crevier ProjectJune 10, 2025 | finanznachrichten.deNiobay Metals Announces the Start of Its 2025 Drill Campaign on Its Crevier ProjectJune 10, 2025 | juniorminingnetwork.comNioBay Metals starts first product deliveries from Quebec’s Crevier projectJune 4, 2025 | msn.comNioBay delivers first products to potential customers from its pilot plantJune 4, 2025 | canadianminingjournal.comCNiobay Metals Makes Its First Product Deliveries to Potential Customers/PartnersJune 3, 2025 | juniorminingnetwork.comNioBay receives $400,000 grant for its Crevier 2 projectApril 9, 2025 | canadianminingjournal.comCNBYCF Niobay Metals Inc.January 28, 2025 | seekingalpha.com Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 2026Big-Tech Earnings: Google and Meta's Results Support Broadcom's OutlookBy Leo Miller | May 4, 2026Memory Money: Data Is the New Oil, and Memory Is the New PipelineBy Jeffrey Neal Johnson | April 16, 2026NBY, BRM, MDNA, and ME Company DescriptionsBioRem CVE:BRMC$3.39 0.00 (0.00%) As of 03:38 PM EasternBioRem Inc., a clean technology engineering company, designs, manufactures, distributes, and sells air pollution control systems that are used to eliminate odors, volatile organic compounds (VOCs), and hazardous air pollutants (HAPs). It offers biofilters for the removal of odors, H2S, VOCs, and HAPs; and biotrickling filters for applications of high levels of H2S or other water-soluble VOCs. The company also provides multi-stage systems to remove odors from various municipal/urban wastewater treatment processes; biogas desulfurization systems; dry scrubber adsorption systems; and cannabis odor control systems. In addition, it offers biological processes and testing services; media sampling and analysis; system review and inspections; and media replacements and spare parts. The company operates in Canada, the United States, China, and internationally. BioRem Inc. was founded in 1990 and is headquartered in Puslinch, Canada.Medicenna Therapeutics TSE:MDNAC$0.62 0.00 (0.00%) As of 03:59 PM EasternMedicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.23andMe NASDAQ:ME23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.Niobay Metals CVE:NBYC$0.08 0.00 (0.00%) As of 03:54 PM EasternNiobay Metals Inc. engages in the acquisition, exploration, and evaluation of mineral properties in Canada. The company explores for niobium, tantalum, titanium, and phosphate properties. It holds 100% interests in the James Bay niobium project that covers an area of 8,833 hectares located in the James Bay Lowlands in northeastern Ontario, Canada; and 72.5% interests in the Crevier niobium and tantalum project that covers 83 contiguous concessions covering a total of 4,645 hectares located to the north of Girardville, in the Lac Saint-Jean region, province of Quebec, Canada. The company also holds 80% interests in the Foothills Project comprising 5 separated claim blocks that covers an area of approximately 285 square kilometers located in Québec. The company was formerly known as MDN Inc. and changed its name to Niobay Metals Inc. in September 2016. Niobay Metals Inc. was incorporated in 1954 and is based in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
